Prevention of MRSA Infection in the Hospital Setting


An infection prevention expert reviews procedures for controlling methicillin-resistant Staphylococcus aureus (MRSA) infections.

Marsha Koopman, RN, MHA, CIC, manager of the department of Hospital Epidemiology/Infection Prevention at UC Davis Health System, presents an update on hospital procedures that can help control the spread of methicillin-resistant Staphylococcus aureus (MRSA) infections in the hospital setting.

Related Videos
Connective Tissue Disease Brings Dermatology & Rheumatology Together
What Makes JAK Inhibitors Safe in Dermatology
Potential JAK Inhibitor Combination Regimens in Dermatology
Therapies in Development for Hidradenitis Suppurativa
"Prednisone without Side Effects": The JAK Inhibitor Ceiling in Dermatology
Discussing Changes to Atopic Dermatitis Guidelines, with Robert Sidbury, MD, MPH
How Will Upadacitinib, Povorcitinib Benefit Hidradenitis Suppurativa?
The JAK Inhibitor Safety Conversation
Jonathan Silverberg, MD, PhD, MPH | Credit: George Washington University
Secukinumab and Bimekizumab for Hidradenitis Suppurativa
© 2024 MJH Life Sciences

All rights reserved.